Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Clin Med Res ; 13(9): 439-459, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34691318

RESUMEN

Microbial therapeutics, which include gut biotics and fecal transplantation, are interventions designed to improve the gut microbiome. Gut biotics can be considered as the administration of direct microbial populations. The delivery of this can be done through live microbial flora, certain food like fiber, microbial products (metabolites and elements) obtained through the fermentation of food products, or as genetically engineered substances, that may have therapeutic benefit on different health disorders. Dietary intervention and pharmacological supplements with gut biotics aim at correcting disruption of the gut microbiota by repopulating with beneficial microorganism leading to decrease in gut permeability, inflammation, and alteration in metabolic activities, through a variety of mechanisms of action. Our understanding of the pharmacokinetics of microbial therapeutics has improved with in vitro models, sampling techniques in the gut, and tools for the reliable identification of gut biotics. Evidence from human studies points out that prebiotics, probiotics and synbiotics have the potential for treating and preventing mental health disorders, whereas with paraprobiotics, proteobiotics and postbiotics, the research is limited at this point. Some animal studies point out that gut biotics can be used with conventional treatments for a synergistic effect on mental health disorders. If future research shows that there is a possibility of synergistic effect of psychotropic medications with gut biotics, then a gut biotic or nutritional prescription can be given along with psychotropics. Even though the overall safety of gut biotics seems to be good, caution is needed to watch for any known and unknown side effects as well as the need for risk benefit analysis with certain vulnerable populations. Future research is needed before wide spread use of natural and genetically engineered gut biotics. Regulatory framework for gut biotics needs to be optimized. Holistic understanding of gut dysbiosis, along with life style factors, by health care providers is necessary for the better management of these conditions. In conclusion, microbial therapeutics are a new psychotherapeutic approach which offer some hope in certain conditions like dementia and depression. Future of microbial therapeutics will be driven by well-done randomized controlled trials and longitudinal research, as well as by replication studies in human subjects.

2.
Discov Med ; 26(143): 137-146, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30586537

RESUMEN

Prescribing medications safely and effectively in older adults is a complex process. This review discusses challenges with medication prescribing in older adults and outlines a holistic approach to medication management in older adults. Well-known challenges including the alterations in pharmacokinetics and pharmacodynamics that often occur with aging are discussed. Other classic concerns including polypharmacy, potentially inappropriate medication use, prescribing cascades, suboptimal prescribing, paradoxical harm and unintended consequences of medications, and drug interactions are reviewed. Newer approaches, including deprescribing, pharmacogenomics, and the future potential for senolytic therapy are also discussed. All healthcare providers should consider these challenges when prescribing medications in older adults. Choosing a drug that fits both a patient's pathophysiology and biology, avoiding drugs with significant side effects, titrating doses, and deprescribing are all critical in optimizing medication therapy.


Asunto(s)
Envejecimiento/patología , Quimioterapia/métodos , Polifarmacia , Pautas de la Práctica en Medicina , Anciano , Anciano de 80 o más Años , Comorbilidad , Quimioterapia/normas , Humanos , Pautas de la Práctica en Medicina/normas , Pautas de la Práctica en Medicina/tendencias
3.
J Gerontol A Biol Sci Med Sci ; 58(4): 362-6, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12663699

RESUMEN

Osteoporosis is a silent epidemic in the world today. With the increase in the elderly population, there will be an increase in the prevalence of osteoporosis, and so the need for focused preventive strategies should become a public health priority. Prophylactic therapy and risk-factor reduction is important, as this is likely to be cost effective. There are scientific observations that point out that vascular dysfunction seen with aging may be related to the pathogenesis of osteoporosis. Here we review this relationship from a different angle. We think aggressive control of vascular risk factors in addition to the known existing osteoporosis risk factors may help to reduce the morbidity and mortality associated with this disease.


Asunto(s)
Huesos/irrigación sanguínea , Osteoporosis/etiología , Osteoporosis/prevención & control , Alcoholismo/complicaciones , Animales , Apolipoproteínas E/genética , Sistema Nervioso Autónomo/fisiopatología , Café/efectos adversos , Complicaciones de la Diabetes , Femenino , Terapia de Reemplazo de Hormonas , Humanos , Hiperlipidemias/complicaciones , Hipertensión/complicaciones , Masculino , Microcirculación , Óxido Nítrico/fisiología , Osteoporosis/epidemiología , Osteoporosis/genética , Factores de Riesgo , Fumar/efectos adversos , Vitamina D/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA